Sara Bonstein Sells 3,470 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 3,470 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $65.70, for a total transaction of $227,979.00. Following the sale, the chief financial officer now directly owns 114,736 shares in the company, valued at $7,538,155.20. This represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sara Bonstein also recently made the following trade(s):

• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The stock was sold at an average price of $63.72, for a total transaction of $67,925.52.

Insmed Stock Performance

Insmed stock opened at $65.25 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53. The stock’s 50 day moving average price is $71.23 and its 200 day moving average price is $72.44. The firm has a market capitalization of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. The company’s quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.10) earnings per share. As a group, sell-side analysts expect that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Truist Financial reiterated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Friday, November 1st. Bank of America boosted their target price on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. increased their price target on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $83.67.

Institutional Trading of Insmed

Hedge funds and other institutional investors have recently modified their holdings of the business. CIBC Asset Management Inc grew its stake in Insmed by 3.5% during the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 149 shares in the last quarter. Commerce Bank grew its position in shares of Insmed by 2.4% during the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 163 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares during the last quarter. Atomi Financial Group Inc. raised its holdings in Insmed by 1.4% in the third quarter. Atomi Financial Group Inc. now owns 23,248 shares of the biopharmaceutical company’s stock valued at $1,697,000 after acquiring an additional 314 shares in the last quarter. Finally, V Square Quantitative Management LLC acquired a new stake in Insmed in the third quarter valued at $30,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.